Evolus, Inc. (EOLS) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Evolus, Inc. (EOLS) Healthcare & Pipeline Overview

Evolus, Inc. focuses on the medical aesthetics market, offering Jeuveau, a botulinum toxin type A product, to physicians and patients in the United States. The company differentiates itself through its focus on performance beauty and a specific formulation targeting glabellar lines, operating within the competitive specialty and generic drug manufacturing sector.

What Is the Investment Thesis for EOLS?

Evolus, Inc. presents a focused investment opportunity within the medical aesthetics market, driven by the increasing demand for non-invasive cosmetic procedures. The company's primary value driver is Jeuveau, a botulinum toxin type A product targeting glabellar lines. Key growth catalysts include expanding market share within the botulinum toxin market, increasing brand awareness among physicians and patients, and potential strategic partnerships. However, investors may want to evaluate risks such as competition from established players, patent protection, and regulatory hurdles. With a market capitalization of $550M and a negative profit margin of -14.4%, Evolus's future profitability hinges on successful commercialization and market penetration of Jeuveau.

Based on FMP financials and quantitative analysis

EOLS Key Highlights

Market Cap of $550M reflects the company's current valuation in the competitive aesthetics market.

• Gross Margin of 65.1% indicates strong pricing power and efficient cost management in the production of Jeuveau.
• Negative Profit Margin of -14.4% highlights the company's ongoing investments in marketing and sales to drive market share growth.
• Beta of 1.00 suggests the stock's volatility is similar to the overall market.
• Evolus has 372 employees, reflecting the scale of its operations and commercialization efforts.

Who Are EOLS's Competitors?

EOLS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are EOLS's Key Strengths?

Proprietary Jeuveau formulation.

• Focus on the growing aesthetics market.
• Experienced management team.
• Established distribution network.

What Are EOLS's Weaknesses?

Limited product portfolio.

• High dependence on Jeuveau sales.
• Negative profit margin.
• Relatively small market capitalization.

What Could Drive EOLS Stock Higher?

Continued expansion of Jeuveau's market share through targeted marketing and sales initiatives.

• Potential new product launches or line extensions to broaden the company's portfolio.
• Strategic partnerships with medical practices and distributors to enhance market reach.
• Positive clinical trial results or regulatory approvals for new indications of Jeuveau.

What Are the Key Risks for EOLS?

Financial-distress signal — its Altman Z-Score of -1.27 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Competition from established players with greater resources and market share.
• Patent litigation or challenges to the company's intellectual property.
• Regulatory changes or adverse events affecting the aesthetics market.
• Economic downturn impacting consumer spending on non-essential cosmetic procedures.
• Dependence on a single product (Jeuveau) makes the company vulnerable to market shifts.

What Are the Growth Opportunities for EOLS?

• Expanding Market Share: Evolus has the opportunity to increase its market share within the botulinum toxin market by targeting new physicians and patients. This can be achieved through targeted marketing campaigns, educational programs, and strategic partnerships with medical practices. Timeline: Ongoing.
• Product Line Expansion: Evolus can expand its product line to include other aesthetic treatments and products, such as dermal fillers and skincare products. This would allow the company to offer a more comprehensive suite of solutions to its customers and increase its revenue streams. Market analysis and strategic acquisitions could accelerate this expansion. Timeline: 2-3 years.
• International Expansion: Evolus can expand its geographic reach beyond the United States by entering new international markets. This would provide access to a larger customer base and diversify its revenue streams. Regulatory approvals and market entry strategies would be critical for success. Timeline: 3-5 years.
• Strategic Partnerships: Evolus can form strategic partnerships with other companies in the aesthetics industry, such as medical device manufacturers and distributors. This would allow the company to leverage the expertise and resources of its partners to accelerate its growth and expand its market reach. Timeline: Ongoing.
• Direct-to-Consumer Marketing: Evolus can implement direct-to-consumer marketing campaigns to increase brand awareness and drive demand for Jeuveau. This would involve targeting potential patients through online advertising, social media, and other channels. Compliance with advertising regulations is essential. Timeline: Ongoing.

What Are EOLS's Competitive Advantages?

• Proprietary Formulation: Jeuveau is a proprietary 900 kilodalton purified botulinum toxin type A formulation.
• Brand Recognition: Building brand recognition in the competitive aesthetics market.
• Established Distribution Network: Developing a strong distribution network with physicians and clinics.
• Regulatory Approvals: FDA approval provides a barrier to entry for new competitors.

What Does EOLS Do?

Evolus, Inc., established in 2012 and headquartered in Newport Beach, California, is a performance beauty company dedicated to providing medical aesthetic products. The company's flagship product is Jeuveau (prabotulinumtoxinA-xvfs), a proprietary 900 kilodalton purified botulinum toxin type A formulation. Jeuveau is specifically designed for the temporary improvement in the appearance of moderate to severe glabellar lines, commonly known as frown lines, in adults. Evolus targets physicians and their patients within the United States, focusing on the growing demand for non-invasive cosmetic procedures. The company's business model centers around the development, commercialization, and marketing of aesthetic products. Evolus aims to establish a strong presence in the competitive aesthetics market by offering a differentiated product with a focus on efficacy and patient satisfaction. The company's strategic focus is on expanding its market share within the botulinum toxin segment and potentially broadening its product portfolio to include other aesthetic treatments.

What Products and Services Does EOLS Offer?

• Develops and commercializes medical aesthetic products.
• Offers Jeuveau, a botulinum toxin type A formulation.
• Targets the temporary improvement of glabellar lines.
• Focuses on the U.S. market.
• Markets products to physicians and their patients.
• Operates within the performance beauty sector.

How Does EOLS Make Money?

• Develops and patents proprietary aesthetic formulations.
• Markets and sells products directly to physicians.
• Generates revenue through product sales.
• Focuses on building brand awareness and market share.

What Industry Does EOLS Operate In?

Evolus, Inc. operates within the dynamic and growing medical aesthetics industry. This sector is characterized by increasing demand for non-invasive cosmetic procedures, driven by an aging population and a growing emphasis on appearance. The market is competitive, with established players like Allergan (AGN) dominating the botulinum toxin segment. Evolus aims to capture market share with Jeuveau, targeting a specific niche within the broader aesthetics market. The industry is subject to regulatory oversight and technological advancements, requiring companies to invest in research and development to maintain a competitive edge.

Who Are EOLS's Key Customers?

• Physicians specializing in aesthetic procedures.
• Medical spas and cosmetic clinics.
• Patients seeking non-invasive cosmetic treatments.
• Dermatologists and plastic surgeons.

Return on equity for Evolus, Inc. stands at 174.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -19.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -9.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.04 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -9.6%, the inverse of the P/E and a quick read on earnings relative to price.

Evolus, Inc. (EOLS) Valuation Context

Valued at $550M, EOLS is classified as a small-cap stock. Relative to its peer group, EOLS's quantitative score of 20/100 is below the peer average of 74/100.

Company Profile

Evolus, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Newport Beach, US. The company is led by CEO David Moatazedi. EOLS has traded publicly since 2018.

Evolus, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.27 places it in the distress zone, a signal of elevated financial risk.

Wall Street analysts project Evolus, Inc. revenue of about $334.3M for fiscal 2026, with EPS near $-0.03. The estimate reflects 5 contributing analysts.

EOLS Financials

EOLS Latest News

EOLS Analyst Consensus

EOLS MoonshotScore

What Investors Ask About Evolus, Inc. (EOLS) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources